Guillaume Foldes-Busque1,2,3, Clermont E Dionne4,5, Stéphane Turcotte6, Phillip J Tully7, Marie-Andrée Tremblay8,6, Paul Poirier9,10, Isabelle Denis8,6. 1. School of Psychology, Université Laval, 2325 rue des Bibliothèques, bureau 1018, Québec, QC, G1V 0A6, Canada. guillaume.foldes-busque@psy.ulaval.ca. 2. Research Center of the Centre Intégré de Santé et de Services Sociaux de Chaudière-Appalaches, Lévis, QC, Canada. guillaume.foldes-busque@psy.ulaval.ca. 3. Research Center of the Quebec Heart and Lung Institute, Québec, QC, Canada. guillaume.foldes-busque@psy.ulaval.ca. 4. Hôpital du Saint-Sacrement, Québec, QC, Canada. 5. Department of Rehabilitation, Faculty of Medicine, Université Laval, Québec, QC, Canada. 6. Research Center of the Centre Intégré de Santé et de Services Sociaux de Chaudière-Appalaches, Lévis, QC, Canada. 7. School of Medicine, The University of Adelaide, Adelaide, Australia. 8. School of Psychology, Université Laval, 2325 rue des Bibliothèques, bureau 1018, Québec, QC, G1V 0A6, Canada. 9. Research Center of the Quebec Heart and Lung Institute, Québec, QC, Canada. 10. Faculty of Pharmacy, Université Laval, Québec, QC, Canada.
Abstract
BACKGROUND: Anxiety is associated with poorer prognosis in patients with coronary artery disease (CAD). Due to their severity and chronic course, anxiety disorders, particularly generalized anxiety disorder (GAD) and panic disorder (PD), are of considerable interest and clinical importance in this population. This study has two main objectives: (1) to estimate the prevalence and incidence of GAD and PD in patients with CAD over a 2-year period and (2) to prospectively assess the association between PD or GAD and adverse cardiac events, treatment adherence, CAD-related health behaviors, quality of life and psychological distress. DESIGN/ METHOD: This is a longitudinal cohort study in which 3610 participants will be recruited following a CAD-related revascularization procedure. They will complete an interview and questionnaires at 5 time points over a 2-year period (baseline and follow-ups after 3, 6, 12 and 24 months). The presence of PD or GAD, adherence to recommended treatments, health behaviors, quality of life and psychological distress will be assessed at each time point. Data regarding mortality and adverse cardiac events will be collected with a combination of interviews and review of medical files. DISCUSSION: This study will provide essential information on the prevalence and incidence of anxiety disorders in patients with CAD and on the consequences of these comorbidities. Such data is necessary in order to develop clear clinical recommendations for the management of PD and GAD in patients with CAD. This will help improve the prognosis of patients suffering from both conditions.
BACKGROUND:Anxiety is associated with poorer prognosis in patients with coronary artery disease (CAD). Due to their severity and chronic course, anxiety disorders, particularly generalized anxiety disorder (GAD) and panic disorder (PD), are of considerable interest and clinical importance in this population. This study has two main objectives: (1) to estimate the prevalence and incidence of GAD and PD in patients with CAD over a 2-year period and (2) to prospectively assess the association between PD or GAD and adverse cardiac events, treatment adherence, CAD-related health behaviors, quality of life and psychological distress. DESIGN/ METHOD: This is a longitudinal cohort study in which 3610 participants will be recruited following a CAD-related revascularization procedure. They will complete an interview and questionnaires at 5 time points over a 2-year period (baseline and follow-ups after 3, 6, 12 and 24 months). The presence of PD or GAD, adherence to recommended treatments, health behaviors, quality of life and psychological distress will be assessed at each time point. Data regarding mortality and adverse cardiac events will be collected with a combination of interviews and review of medical files. DISCUSSION: This study will provide essential information on the prevalence and incidence of anxiety disorders in patients with CAD and on the consequences of these comorbidities. Such data is necessary in order to develop clear clinical recommendations for the management of PD and GAD in patients with CAD. This will help improve the prognosis of patients suffering from both conditions.
Authors: Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert Journal: J Am Coll Cardiol Date: 2011-11-03 Impact factor: 24.094
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Guillaume Foldes-Busque; Isabelle Denis; Julien Poitras; Richard P Fleet; Patrick M Archambault; Clermont E Dionne Journal: Health Psychol Date: 2018-09 Impact factor: 4.267
Authors: Walter Swardfager; Nathan Herrmann; Susan Marzolini; Mahwesh Saleem; Shale B Farber; Alexander Kiss; Paul I Oh; Krista L Lanctôt Journal: J Clin Psychiatry Date: 2010-11-02 Impact factor: 4.384
Authors: Michelle G Newman; Sandra J Llera; Thane M Erickson; Amy Przeworski; Louis G Castonguay Journal: Annu Rev Clin Psychol Date: 2013 Impact factor: 18.561